- Clario’s third annual ESG report for calendar year 2023 highlights advancements in responsible artificial intelligence (AI), investments in employee programs, and ambitious science-based sustainability goals.
- The report highlights initiatives such as the CORE onboarding program for new hires, leadership training through the Manager Essentials program, and our commitment to ethical data use and privacy, as embodied in our Responsible Use of AI Principles.
- Clario is committed to achieving net-zero emissions by 2045, with interim targets developed for validation by the Science-Based Targets initiative, and to achieving ISO 14001:2015 certification for resource efficiency and waste reduction.
PHILADELPHIA , August 20, 2024 /PRNewswire/ — Clarioa healthcare research technology company that provides cutting-edge technology solutions for clinical trials, today released its third annual Environmental, Social and Governance (ESG) Report for calendar year 2023. Key aspects of the report include the development of principles governing the company’s responsible use of artificial intelligence (AI), new investments in employee development programs, and a submission for validation of scientific targets critical to its sustainable growth and ethical business operations.
“At Clario, data science and quality are the backbone of every technology, product and service we provide to our customers,” said Chris FikryGeneral manager. “As we reflect on our third ESG report, I am proud of the progress we continue to make. This report reaffirms our relentless commitment to responsibly advancing technology, investing in our people, and driving ambitious climate action. Our mission to help our customers deliver better lives through innovation shines through in these efforts.”
Notable highlights of the report include:
Advancing technologies responsibly: Last year, Clario strengthened its commitment to ethical AI by establishing five organizational principles to govern the company’s responsible use of AI. Since 2018, Clario has leveraged AI solutions across its technology platform to accelerate clinical data collection, reduce data variability, and enhance patient privacy, thereby increasing the quality and accuracy of clinical data capture. By ethically developing and implementing AI, Clario is advancing clinical trial endpoint analytics and improving the sponsor experience.
Investments in employee programs: The Clario Onboarding Readiness Experience (CORE) program is a major initiative launched in 2023, with the goal of welcoming all new employees and immersing them in the company’s culture, values, and purpose. The CORE program fosters a sense of belonging and fosters team cohesion. Additionally, the Manager Essentials Program (MEP) made great strides in 2023, with new people leaders globally participating in leadership training focused on culture, engagement, vision, strategy, and coaching. These employee programs strengthen leadership culture and promote inclusion.
Science-based goals: In 2023, Clario aligned its sustainability goals with the Paris Climate Agreement’s “well below 2.0 degrees” trajectory. Clario submitted ambitious emissions reduction targets for validation by the Science-Based Targets Initiative (SBTi), aiming for net-zero emissions by 2045. Clario achieved significant reductions in its direct greenhouse gas (GHG) emissions in 2023 by implementing strategic office consolidations for remote work flexibility and working with key stakeholders across the value chain. These efforts contributed to a 20% year-over-year reduction in the company’s GHG emissions. Additionally, Clario’s Estenfeld, Germany The facilities have achieved ISO 14001:2015 certification, in recognition of their commitment to resource efficiency and waste reduction.
“Defining these goals is essential to drive innovation and create value while taking into account environmental impacts,” said Ellen StreetExecutive Vice President, Digital Physiology and ESG Executive Sponsor“Our commitment to combating climate change is about leading by example and working towards a sustainable future for our customers and communities. Achieving ISO 14001:2015 certification supports our commitment to responsible practices and continuous improvement, which ultimately benefits our customers and their patients around the world.”
To access Clario’s third annual Environmental, Social and Governance (ESG) Report, visit Clario.com.
About Clario
Clario is a leading healthcare research and technology company that generates high-quality clinical evidence for our pharmaceutical, biotech and medical device partners. We offer comprehensive evidence generation solutions that combine eCOA, cardiac solutions, medical imaging, precision motion and respiratory endpoints.
Since its founding over 50 years ago, Clario has delivered deep scientific expertise and cutting-edge technologies to help transform the lives of patients around the world. Our endpoint data solutions have supported clinical trials over 26,000 times in more than 100 countries. Our global team of scientific, technological and operational experts has supported over 60% of all FDA new drug approvals since 2012.
For more information, visit Clario.com or follow us on LinkedIn.
Contact details
(protected email)
SOURCE Clario
